Pre-treatment gut microbiome and salivary metabolome signatures associate with chemotherapy-induced cognitive decline in women with breast cancer: A prospective pilot study
Date
2026
Authors
Cross, C.B.
Bowen, J.M.
Leifert, W.R.
Beale, D.J.
Francois, M.
Joshi, R.
Fosh, B.G.
Coller, J.K.
Tuke, J.
Bareham, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Cancer Letters, 2026; 640:218234-1-218234-5
Statement of Responsibility
Courtney B. Cross, Joanne M. Bowen, Wayne R. Leifert, David J. Beale, Maxime Francois, Rohit Joshi, Beverley G. Fosh, Janet K. Coller, Jonathan Tuke, Monique Bareham, Denelle J. Cosier, Linh Hang To, Feargal J. Ryan, Hannah R. Wardill
Conference Name
Abstract
Chemotherapy remains the primary treatment for advanced cancers and while efficacious, it causes widespread cytotoxicity and a battery of side effects. Of these, chemotherapy-induced cognitive impairment (CICI) has been consistently identified as an unmet need [1]. Experienced by up to 75 % of people in the acute treatment setting and 40 % following treatment cessation [2], CICI impacts almost all facets of a person's cognitive capacity. This impairs adherence to long-term therapies, academic and vocational performance and is thus a major cause of un(der)-employment as well as financial and psychosocial distress [1].
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies